The U.S. Food and Drug Administration issued a complete response letter (CRL) to Corcept Therapeutics for relacorilant in the indication of hypertension secondary to hypercortisolism (Cushing syndrome), requesting additional evidence of efficacy. The CRL knocked down hopes for a 2026 launch in that endocrine indication and sent Corcept’s shares sharply lower. Corcept said it will meet with the agency to discuss next steps on the Cushing program while shifting commercial and regulatory focus to a July 2026 PDUFA target for relacorilant in platinum‑resistant ovarian cancer. The company is now prioritizing the oncology filing and additional data generation to address the agency’s efficacy concerns. Investors and collaborators will watch how Corcept sequences further engagement with the FDA and whether new or supplemental data can reopen the endocrine pathway or strengthen the oncology filing.